SCHEMBL5714477

SCHEMBL5714477

O=C(Oc1ccc(CCOc2ccncc2)cc1)N1CCN(c2ccc(F)cn2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ME2 P23368 4/20 0.50
ME1 P48163 4/20 0.50
ME3 Q16798 4/20 0.50
PANK3 Q9H999 1/20 0.46
ALOX15 P16050 1/20 0.44
HRH3 Q9Y5N1 4/20 0.44
DRD2 P14416 2/20 0.44
DRD1 P21728 2/20 0.44
DRD5 P21918 2/20 0.44
DRD3 P35462 2/20 0.44
SLC6A7 Q99884 1/20 0.42
F10 P00742 1/20 0.42
CHRM1 P11229 1/20 0.42
PRKAA2 P54646 2/20 0.42
TRPA1 O75762 1/20 0.41
EPHX2 P34913 1/20 0.41
HRH1 P35367 2/20 0.41
HTR1A P08908 1/20 0.41
ADRA2C P18825 1/20 0.41
HTR2A P28223 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714971 0.90 ME2 (0.48) ME2ME1ME3PANK3ALOX15
SCHEMBL5714406 0.88 ME2 (0.50) ME2ME1ME3PANK3HRH3
SCHEMBL5714506 0.88 TRPA1 (0.49) ME2ME1ME3PANK3HRH3
SCHEMBL5714729 0.88 ME2 (0.46) ME2ME1ME3PANK3ALOX15
SCHEMBL5714123 0.88 SMN1; SMN2 (0.57) ME2ME1ME3HRH3TRPA1
SCHEMBL5715214 0.87 SLC6A7 (0.48) ME2ME1ME3PANK3HRH3
SCHEMBL5714828 0.87 ME2 (0.47) ME2ME1ME3PANK3SLC6A7
SCHEMBL5715291 0.86 ME2 (0.48) ME2ME1ME3PANK3ALOX15
SCHEMBL5714610 0.85 HSD17B10 (0.54) HRH3DRD2DRD1DRD5DRD3
SCHEMBL5715126 0.83 KDM4E (0.50) ME2ME1ME3PANK3HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC ME2 854/4885ME1 2914/4885ME3 1308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.